Motif Neurotech is a technology company.
Motif Neurotech has raised $19.0M across 1 funding round.
Motif Neurotech has raised $19.0M in total across 1 funding round.
Motif Neurotech has raised $19.0M in total across 1 funding round.
Motif Neurotech's investors include Satori Capital, Blake Mycoskie.
Motif Neurotech is a Houston-based therapeutic brain-computer interface (BCI) company developing minimally invasive neuromodulation devices for mental health disorders, primarily treatment-resistant depression (TRD), a form of major depressive disorder affecting patients unresponsive to medications.[1][2][3] Their lead product, DOT, is a pea-sized, wireless, battery-free microstimulator implanted in a 20-minute outpatient procedure, pairing with a wearable headset to deliver at-home electrical stimulation that restores healthy brain circuit activity by targeting the Central Executive Network and countering rumination-linked Default Mode Network dominance.[1][3][4][6][8] Serving patients failed by drugs (about 1 in 3 with depression), Motif solves accessibility barriers in neuromodulation through cosmetic invisibility, minimal side effects, and precise, non-brain-contacting stimulation, with early human trials demonstrating safety and efficacy.[1][4] The company shows strong growth momentum, including a $18.75 million Series A round in 2024 to fund clinical studies and a first-in-human brain stimulation milestone.[4]
Motif Neurotech was founded in 2022 by Rice University faculty Jacob Robinson, Ph.D. (CEO)—an expert in wireless magnetoelectric power transfer technology—and Kaiyuan Yang, alongside Baylor College of Medicine physicians Sunil Sheth and neurosurgeon Sameer Sheth, M.D., Ph.D. (Co-Founder), emerging from Robinson's Rice lab.[2][3][4][7] The idea stemmed from advancing miniature bioelectronics for neuropsychiatric treatment, leveraging Rice's wireless tech to create the world's smallest implantable brain stimulator, avoiding invasive deep brain methods.[1][3][4] Early traction included large animal studies lasting over 30 days, a medRxiv preprint on human intraoperative safety, and the first-in-human implantation for TRD in 2023, marking a pivotal shift toward outpatient, at-home therapy.[1][4]
Motif rides the brain-computer interface (BCI) and neuromodulation wave for mental health, shifting from pharmaceuticals to bioelectronics amid rising TRD prevalence (30% non-responders to multiple drugs) and demand for non-drug options.[1][4][6] Timing aligns with advances in wireless power (from Rice tech) and minimally invasive implants, making neuromodulation as routine as cardiac pacemakers, amid a BCI race featuring Neuralink competitors.[1][3][6] Market forces like mental health stigma reduction, interventional psychiatry growth, and FDA interest in outpatient neurotech favor Motif, influencing the ecosystem by pioneering surface-cortex stimulation for depression, PTSD, and anxiety—potentially expanding BCI beyond motor applications to 1 billion+ global mental health patients.[3][4][7]
Motif is poised to launch DOT clinical trials for TRD approval, scaling from human proof-of-concept to widespread outpatient deployment, with Series A funds accelerating R&D for additional indications like anxiety and PTSD.[4][6][7] Trends in AI-driven stimulation patterns, lived-experience integration, and bioelectronic convergence will shape their path, potentially disrupting $20B+ depression markets by making precision neuromodulation accessible.[1][6][8] Their influence may evolve from Rice spinout pioneer to category leader in therapeutic BCI, redefining mental health as an "electrical deficiency" treatable at home—echoing the high-level promise of stigma-free, effective relief for treatment-resistant patients.[1][3][6]
Motif Neurotech has raised $19.0M across 1 funding round. Most recently, it raised $19.0M Series A in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2024 | $19.0M Series A | Satori Capital, Blake Mycoskie |